Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial

Annals of Oncology

Volumn 24, Issue 5, 2013, Pages 1253-1261

  Okines, A F C ^a   Thompson, L C ^b   Cunningham, D ^a   Wotherspoon, A ^a   Reis filho, J S ^c   Langley, R E ^b   Waddell, T S ^a   Noor, D ^b   Eltahir, Z ^a   Wong, R ^a   Stenning, S ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Adenocarcinoma; Gastric; HER2; Immunohistochemistry; In situ hybridisation; Oesophageal

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; EARLY CANCER; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; ESOPHAGUS RESECTION; FEMALE; GASTRECTOMY; GENE; GENE OVEREXPRESSION; HER2 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; TISSUE MICROARRAY;

EID: 84877103264     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds622     Document Type: Article

References (35)

1. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
2. Ychou M, Boige V, Pignon JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29(13): 1715-1721.
3. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
4. Dhesy-Thind B, Pritchard KI, Messersmith H et al. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 2008; 109: 209-229.
5. Gennari A, Sormani MP, Pronzato P et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100: 14-20.
6. Jarvinen TA, Holli K, Kuukasjarvi T et al. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998; 77: 2267-2273.
7. Bartlett JM, Munro A, Cameron DA et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 2008; 26: 5027-5035.
8. Press MF, Sauter G, Buyse M et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011; 29: 859-867.
9. Arriola E, Lambros MB, Jones C et al. Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. Lab Invest 2007; 87: 75-83.
10. Kellner U, Sehested M, Jensen PB et al. Culprit and victim-DNA topoisomerase II. Lancet Oncol 2002; 3: 235-243.
11. Allgayer H, Babic R, Gruetzner KU et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumorassociated protease systems. J Clin Oncol 2000; 18: 2201-2209.
12. Grabsch H, Sivakumar S, Gray S et al. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65.
13. Pinto-de-Sousa J, David L, Almeida R et al. c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002; 10: 247-256.
14. Tanner M, Hollmen M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273-278.
15. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
16. Ruschoff J, Dietel M, Baretton G et al. HER2 diagnostics in gastric cancerguideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457: 299-307.
17. Hamilton SR, Aaltonen LA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press 2000.
18. Tan DS, Marchio C, Jones RL et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27-44.
19. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M et al. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol 2008; 3: 41.
20. EMEA. In Edition 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000278/WC500059913.pdf (28 November 2009, date last accessed).
21. FDA. In Edition 2010. http://www.cancer.gov/cancertopics/druginfo/fdatrastuzumab# Anchor-Gastric (28 November 2012, date last accessed).
22. Bang Y, Chung H, Xu J et al. Seoul National University Hospital, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Affiliated Hospital (307 Hospital) Cancer Centre, Beijing, China; National Centre for Tumour Diseases, Heidelberg, Germany; Aichi Cancer Center, Nagoya, Japan; Bashkirian Republican Clinical Oncology Dispensary, Ufa, Russia; F. Hoffmann-La Roche, Basel, Russia; Roche Products Ltd, Welwyn Garden City, United Kingdom; TARGOS Molecular Pathology GmbH, Kassel, Germany; University Hospital Gasthuisberg, Leuven, Belgium. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009; 27: 15s (Suppl; abstr 4556).
23. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011; 58: 383-394.
24. Terashima M, Kitada K, Ochiai A et al.; for the ACTS-GC Group. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012; 18(21): 5992-6000.
25. Yoon HH, Shi Q, Sukov WR et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012; 18(2): 546-554.
26. Begnami MD, Fukuda E, Fregnani JHTG et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011.
27. Janjigian YY, Werner D, Pauligk C et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23(10): 2656-2662.
28. Landis JR, GG K. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
29. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-1184.
30. Risio M, De Rosa G, Sarotto I et al. HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int J Oncol 2003; 23: 1381-1387.
31. Yano T, Doi T, Ohtsu A et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15: 65-71.
32. van de Ven S, Smit VT, Dekker TJ et al. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 2010.
33. Knoop AS, Knudsen H, Balslev E et al. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483-7490.
34. Di Leo A, Desmedt C, Bartlett JM et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 2011; 12: 1134-1142.
35. Maresch J, Schoppmann SF, Thallinger CM et al. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment. Crit Rev Oncol Hematol 2012; 82: 310-322.